Tlr4 Inhibitor Attenuates Amyloid-Beta-Induced Angiogenic And Inflammatory Factors In Arpe-19 Cells: Implications For Age-Related Macular Degeneration

Li Chen,Yujing Bai,Min Zhao,Yanrong Jiang
DOI: https://doi.org/10.3892/mmr.2016.4890
IF: 3.423
2016-01-01
Molecular Medicine Reports
Abstract:Subretinally-deposited amyloid-beta (A beta) is an important factor in age-related macular degradation (AMD) often leading to irreversible blindness in the elderly population. The molecular mechanism underlying A beta deposition during AMD remains unclear. The expression of inflammatory and angiogenic factors was examined by treatment of retinal pigment epithelial (RPE) cells with the oligomeric form of A beta (OA beta 1-42). Changes in the mRNA expression levels of various cytokines was detected by the QuantiGenePlex 6.0 Reagent system, and the protein expression level was determined by western blotting. Culture supernatants were detected using a multiplex cytokine assay and enzyme-linked immunosorbent assays. The in vitro tube formation was evaluated by a Matrigel assay. The present study highlights that OA beta 1-42 activates the toll-like receptor 4 (TLR4), myeloid differentiation factor 88 and phosphorylation nuclear factor-kappa B signaling pathway in RPE cells. Additionally, it increased the mRNA and protein expression of interleukin (IL)-6, IL-8, IL-33, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiopoietin 2. Furthermore, the TLR4 inhibitor (COBRA) attenuated the expression of inflammatory and angiogenesis factors, particularly IL-6, IL-8, IL-33, bFGF and VEGF. When human umbilical vein endothelial cells (HUVECs) were co-cultured with the COBRA-treated RPE cell culture supernatant the length of the endothelial cell network (measured by calculating tip cell lengths of endothelial cells) was impaired when compared with the HUVECs that were co-cultured with the cell supernatant exposed to OA beta 1-42. These results suggest that the TLR4-associated pathway may be a potential target for the treatment of AMD.
What problem does this paper attempt to address?